EI

272.7

+2.21%↑

SAN

79.21

-1.69%↓

MRK1

107.2

-0.37%↓

SHL.DE

47.88

-0.19%↓

ARGX

639

-1.3%↓

EI

272.7

+2.21%↑

SAN

79.21

-1.69%↓

MRK1

107.2

-0.37%↓

SHL.DE

47.88

-0.19%↓

ARGX

639

-1.3%↓

EI

272.7

+2.21%↑

SAN

79.21

-1.69%↓

MRK1

107.2

-0.37%↓

SHL.DE

47.88

-0.19%↓

ARGX

639

-1.3%↓

EI

272.7

+2.21%↑

SAN

79.21

-1.69%↓

MRK1

107.2

-0.37%↓

SHL.DE

47.88

-0.19%↓

ARGX

639

-1.3%↓

EI

272.7

+2.21%↑

SAN

79.21

-1.69%↓

MRK1

107.2

-0.37%↓

SHL.DE

47.88

-0.19%↓

ARGX

639

-1.3%↓

Search

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

59.85 -0.99

Résumé

Variation du prix de l'action

24h

Actuel

Min

59.45

Max

60.7

Chiffres clés

By Trading Economics

Revenu

3.9M

27M

Ventes

4.8M

160M

P/E

Moyenne du Secteur

23.07

35.664

BPA

0.423

Rendement du dividende

1.56

Marge bénéficiaire

16.767

Employés

2,188

EBITDA

4.2M

35M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+33.53% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.56%

3.12%

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

235M

3.1B

Ouverture précédente

60.84

Clôture précédente

59.85

Sentiment de l'Actualité

By Acuity

56%

44%

327 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 sept. 2025, 22:39 UTC

Acquisitions, Fusions, Rachats

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept. 2025, 16:43 UTC

Principaux Mouvements du Marché

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept. 2025, 16:42 UTC

Principaux Mouvements du Marché

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept. 2025, 16:35 UTC

Principaux Mouvements du Marché

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept. 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept. 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

CSL Expects Commercial Launch in 2029

15 sept. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept. 2025, 21:15 UTC

Acquisitions, Fusions, Rachats

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept. 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sept. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept. 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept. 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 sept. 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept. 2025, 17:50 UTC

Acquisitions, Fusions, Rachats

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept. 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept. 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

33.53% hausse

Prévisions sur 12 Mois

Moyen 80.85 EUR  33.53%

Haut 90 EUR

Bas 71.7 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

327 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat